자폐 스펙트럼 장애 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has recently published a detailed report on the global Autism Spectrum Disorder (ASD) therapeutics market, providing an in-depth analysis of crucial market dynamics such as drivers, trends, opportunities, and challenges. This report offers valuable insights into the market structure, along with exclusive data and statistics that underscore the expected growth trajectory of the ASD therapeutics market from 2024 to 2031.

Key Insights:

• Estimated Market Size (2024): US$2.14 Bn
• Projected Market Value (2031): US$3.46 Bn
• Global Market Growth Rate (CAGR 2024-2031): 7.1%

ASD Therapeutics Market - Report Scope:

The ASD therapeutics market is propelled by a growing awareness of the disorder and an increasing focus on early diagnosis and intervention. These therapies are crucial for addressing the symptoms and challenges faced by individuals with ASD, including social communication deficits, behavioral issues, and sensory sensitivities. The market growth is driven by advancements in pharmacological treatments, behavioral therapies, and the integration of technology in therapeutic approaches, including digital therapeutics and telehealth solutions.

Market Growth Drivers:

Several factors are contributing to the growth of the global ASD therapeutics market. The rising prevalence of ASD globally has led to an increased demand for effective therapeutic solutions. Additionally, advancements in research have resulted in the development of innovative medications and therapies that target specific symptoms associated with ASD. The growing acceptance of behavioral therapies and a surge in government initiatives and funding for ASD research and awareness are also significant drivers of market growth. Furthermore, the adoption of personalized medicine approaches tailored to the unique needs of individuals with ASD is expected to enhance treatment outcomes.

Market Restraints:

Despite promising growth, the ASD therapeutics market faces several challenges. The high cost of advanced therapies and medications can limit accessibility for many families. Additionally, the lack of standardized treatment protocols and variability in treatment responses can complicate therapeutic strategies. Stigma surrounding mental health and developmental disorders may also deter families from seeking necessary treatments. Moreover, regulatory hurdles related to the approval of new therapies can pose challenges for market entrants.

Market Opportunities:

The ASD therapeutics market presents significant growth opportunities, particularly with the increasing investment in research and development aimed at understanding the underlying mechanisms of ASD. The rising interest in digital health solutions and teletherapy is creating new avenues for delivering therapeutic interventions. Additionally, collaborations between pharmaceutical companies, healthcare providers, and research institutions to develop targeted therapies and comprehensive treatment plans hold great promise for the future of ASD therapeutics.

Key Questions Addressed in the Report:

• What are the primary factors driving global growth in the ASD therapeutics market?
• Which therapeutic modalities are gaining traction in the treatment of ASD?
• How are technological advancements influencing the competitive landscape?
• Who are the leading market players, and what strategies are they employing to enhance their market presence?
• What emerging trends and opportunities are shaping the future of the ASD therapeutics market?

Competitive Intelligence and Business Strategy:

Key players in the global ASD therapeutics market, including Johnson & Johnson, Roche, and Pfizer, are focusing on innovation and product differentiation to gain a competitive edge. These companies are investing in research and development to create effective therapies that address specific symptoms of ASD. Strategic partnerships with organizations and advocacy groups focused on autism are also being pursued to enhance their outreach and market positioning. Moreover, an emphasis on patient-centered approaches and the development of evidence-based therapies is helping these companies meet evolving industry standards and the needs of families affected by ASD.

Key Companies Profiled:

• Curemark LLC
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Novartis AG.
• Eli Lilly and Company
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Yamo Pharmaceuticals
• F. Hoffman-La Roche Ltd.
• Axial Therapeutics Inc.

Market Segmentation

By Drug Therapy

• Antipsychotic Drug
• Antidepressants
• Stimulants

By Disease

• Autistic Disorder
• Asperger Syndrome
• Pervasive Development Disorder

By Age Group

• Children
• Adults

By Region

• North America
• Latin America
• Europe
• South Asia & Oceania
• East Asia
• The Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Autism Spectrum Disorder Therapeutics Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global GDP Growth Outlook
  • 2.3.2. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Disease Epidemiology
• 3.3. Regulatory Landscape
• 3.4. Value Chain Analysis
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Autism Spectrum Disorder Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Global Autism Spectrum Disorder Therapeutics Market Outlook: Drug Therapy
  • 4.1.1. Introduction / Key Findings
  • 4.1.2. Historical Market Size (US$ Mn) Analysis, By Drug Therapy, 2019-2023
  • 4.1.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Therapy, 2024-2031
    • 4.1.3.1. Antipsychotic Drug
    • 4.1.3.2. Antidepressants
    • 4.1.3.3. Stimulants
• 4.2. Market Attractiveness Analysis: Drug Therapy
• 4.3. Global Autism Spectrum Disorder Therapeutics Market Outlook: Disease
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Disease, 2019-2023
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Disease, 2024-2031
    • 4.3.3.1. Autistic Disorder
    • 4.3.3.2. Asperger Syndrome
    • 4.3.3.3. Pervasive Development Disorder
• 4.4. Market Attractiveness Analysis: Disease
• 4.5. Global Autism Spectrum Disorder Therapeutics Market Outlook: Age Group
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Age Group, 2019-2023
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Age Group, 2024-2031
    • 4.5.3.1. Children
    • 4.5.3.2. Adults
• 4.6. Market Attractiveness Analysis: Age Group

5. Global Autism Spectrum Disorder Therapeutics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Autism Spectrum Disorder Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Pricing Analysis
• 6.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 6.3.1. By Country
  • 6.3.2. By Drug Therapy
  • 6.3.3. By Disease
  • 6.3.4. By Age Group
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 6.4.1. U.S.
  • 6.4.2. Canada
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Therapy, 2024-2031
  • 6.5.1. Antipsychotic Drug
  • 6.5.2. Antidepressants
  • 6.5.3. Stimulants
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease, 2024-2031
  • 6.6.1. Autistic Disorder
  • 6.6.2. Asperger Syndrome
  • 6.6.3. Pervasive Development Disorder
• 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Age Group, 2024-2031
  • 6.7.1. Children
  • 6.7.2. Adults
• 6.8. Market Attractiveness Analysis

7. Europe Autism Spectrum Disorder Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 7.3.1. By Country
  • 7.3.2. By Drug Therapy
  • 7.3.3. By Disease
  • 7.3.4. By Age Group
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. U.K.
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Russia
  • 7.4.7. Turkiye
  • 7.4.8. Rest of Europe
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Therapy, 2024-2031
  • 7.5.1. Antipsychotic Drug
  • 7.5.2. Antidepressants
  • 7.5.3. Stimulants
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease, 2024-2031
  • 7.6.1. Autistic Disorder
  • 7.6.2. Asperger Syndrome
  • 7.6.3. Pervasive Development Disorder
• 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Age Group, 2024-2031
  • 7.7.1. Children
  • 7.7.2. Adults
• 7.8. Market Attractiveness Analysis

8. East Asia Autism Spectrum Disorder Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 8.3.1. By Country
  • 8.3.2. By Drug Therapy
  • 8.3.3. By Disease
  • 8.3.4. By Age Group
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. South Korea
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Therapy, 2024-2031
  • 8.5.1. Antipsychotic Drug
  • 8.5.2. Antidepressants
  • 8.5.3. Stimulants
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease, 2024-2031
  • 8.6.1. Autistic Disorder
  • 8.6.2. Asperger Syndrome
  • 8.6.3. Pervasive Development Disorder
• 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Age Group, 2024-2031
  • 8.7.1. Children
  • 8.7.2. Adults
• 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Autism Spectrum Disorder Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 9.3.1. By Country
  • 9.3.2. By Drug Therapy
  • 9.3.3. By Disease
  • 9.3.4. By Age Group
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 9.4.1. India
  • 9.4.2. Southeast Asia
  • 9.4.3. ANZ
  • 9.4.4. Rest of South Asia & Oceania
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Therapy, 2024-2031
  • 9.5.1. Antipsychotic Drug
  • 9.5.2. Antidepressants
  • 9.5.3. Stimulants
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease, 2024-2031
  • 9.6.1. Autistic Disorder
  • 9.6.2. Asperger Syndrome
  • 9.6.3. Pervasive Development Disorder
• 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Age Group, 2024-2031
  • 9.7.1. Children
  • 9.7.2. Adults
• 9.8. Market Attractiveness Analysis

10. Latin America Autism Spectrum Disorder Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 10.3.1. By Country
  • 10.3.2. By Drug Therapy
  • 10.3.3. By Disease
  • 10.3.4. By Age Group
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 10.4.1. Brazil
  • 10.4.2. Mexico
  • 10.4.3. Rest of Latin America
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Therapy, 2024-2031
  • 10.5.1. Antipsychotic Drug
  • 10.5.2. Antidepressants
  • 10.5.3. Stimulants
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease, 2024-2031
  • 10.6.1. Autistic Disorder
  • 10.6.2. Asperger Syndrome
  • 10.6.3. Pervasive Development Disorder
• 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Age Group, 2024-2031
  • 10.7.1. Children
  • 10.7.2. Adults
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Autism Spectrum Disorder Therapeutics Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Pricing Analysis
• 11.3. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
  • 11.3.1. By Country
  • 11.3.2. By Drug Therapy
  • 11.3.3. By Disease
  • 11.3.4. By Age Group
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
  • 11.4.1. GCC Countries
  • 11.4.2. Egypt
  • 11.4.3. South Africa
  • 11.4.4. Northern Africa
  • 11.4.5. Rest of Middle East & Africa
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Therapy, 2024-2031
  • 11.5.1. Antipsychotic Drug
  • 11.5.2. Antidepressants
  • 11.5.3. Stimulants
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease, 2024-2031
  • 11.6.1. Autistic Disorder
  • 11.6.2. Asperger Syndrome
  • 11.6.3. Pervasive Development Disorder
• 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Age Group, 2024-2031
  • 11.7.1. Children
  • 11.7.2. Adults
• 11.8. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Curemark LLC
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Bristol-Myers Squibb Company
  • 12.3.3. Merck & Co., Inc.
  • 12.3.4. Novartis AG.
  • 12.3.5. Eli Lilly and Company
  • 12.3.6. Pfizer Inc.
  • 12.3.7. Johnson & Johnson Services Inc.
  • 12.3.8. Otsuka Pharmaceutical Co., Ltd.
  • 12.3.9. Yamo Pharmaceuticals
  • 12.3.10. F. Hoffman-La Roche Ltd.
  • 12.3.11. Axial Therapeutics Inc.
  • 12.3.12. Others

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations